The second most frequent is hypophysitis, which has been reported in between 5.6% and 13.6% of patients treated with the CTLA4 inhibitor ipilimumab [5,6], but is less common with other ICI: the reported frequency is between 0.5 and 1.1% for PD1 inhibitors [5,6], and less than 0.1% for PDL1 inhibitors [4]. The gene discussed is CD274; the disease is hypophysitis.